1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. SHP2

SHP2

Src homology phosphatase 2; PTPN11

Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-139467
    PF-04577806
    Inhibitor
    PF-04577806 is a potent, selective and ATP competitive PKC inhibitor. PF-04577806 shows potent inhibitory activity towards PKCα, PKCβI, PKCβII, PKCγ, and PKCθ with IC50s of 2.4 nM, 8.1 nM, 6.9 nM, 45.9 nM, and 29.5 nM, respectively. PF-04577806 can reverse retinal vascular leakage in diabetic rats.
    PF-04577806
  • HY-161360
    LXQ-217
    Inhibitor
    LXQ-217 is an oral active SHP2 inhibitor with the IC50 of 2.01 μM. LXQ-217 induces apoptosis and inhibits cell growth in vivo and in vitro.
    LXQ-217
  • HY-155098
    CNBCA
    Inhibitor
    CNBCA is a potent, selective, competitive SHP2 enzyme inhibitor, with the IC50 of 0.87 μM. CNBCA binds to full-length SHP2 and inhibits enzyme activity. CNBCA inhibits pAkt and pERK1/2, and the cell growth of BT474 and MDA-MB468 cells. CNBCA can be used for breast cancer study.
    CNBCA
  • HY-157888
    SHP2-IN-26
    Inhibitor
    SHP2-IN-26 (Compound 4b) is a highly selective SHP2 allosteric inhibitor with a IC50 value of 3.2 nM. SHP2-IN-26 inhibits the phosphorylation of ERK and AKT in NCI-H358 cells. SHP2-IN-26 has antitumor activity.
    SHP2-IN-26
  • HY-139466
    PF-03622905
    Inhibitor
    PF-03622905 is a potent and ATP-competitive PKC inhibitor with IC50s of 5.6 nM, 14.5 nM, 13 nM, 37.7 nM, and 74.1 nM for PKCα, PKCβI, PKCβII, PKCγ, and PKCθ, respectively. PF-03622905 shows high specificity for PKC over other protein kinases.
    PF-03622905
  • HY-155273
    SHP2-IN-17
    SHP2-IN-17 (compound 192) is a SHP2 inhibitor with an IC50 value of 2 nM. SHP2-IN-17 can be used for glioblastoma research.
    SHP2-IN-17
  • HY-162233
    SHP2-IN-25
    Inhibitor
    SHP2-IN-25 (Compound 6) is a SHP2 allosteric inhibitor, with an IC50 of 225 nM. SHP2-IN-25 can be used for the research of cancer.
    SHP2-IN-25
  • HY-172916
    LC-SF-14
    Inhibitor
    LC-SF-14 is a selective dual inhibitor of SHP2 and FGFR (IC50 values are 71.6 and 8.9 nM, respectively). LC-SF-14 inhibits FGFR2-FRS2α-SHP2-MAPK signaling and ERK phosphorylation. LC-SF-14 inhibits the proliferation of KATOIII cancer cells (IC50: 9.2 nM). LC-SF-14 has antitumor activity in the SNU-16 xenograft mouse model. LC-SF-14 can be used in FGFR2-driven gastric cancer research.
    LC-SF-14
  • HY-173573
    TK-684
    Inhibitor
    TK-684 is a potent and selective allosteric SHP2 inhibitor with IC50 values of 2.1, >1000 nM for SHP2WT, SHP22PTP, respectively. TK-684 inhibits cell proliferation and induces apoptosis. TK-684 decreases the protein expression of p-AKT, p-ERK.
    TK-684
  • HY-172454
    SHP2-IN-36
    Inhibitor
    SHP2-IN-36 (Compound B8) is an allosteric inhibitor of SHP2, with an IC50 value of 9.0 nM. In addition, its IC50 for p-ERK is 40 nM. SHP2-IN-36 also exhibited significant antitumor activity in the KYSE520 xenograft mouse model. SHP2-IN-36 can be used for research in the field of anti-tumor .
    SHP2-IN-36
  • HY-155275
    SHP2-IN-19
    SHP2-IN-19 (compound 183) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-19 can be used for glioblastoma research.
    SHP2-IN-19
  • HY-125260
    SHP844
    Inhibitor
    SHP844 is a SHP2 inhibitor with the IC50 of 18.9 µM. SHP2 is a protein tyrosine phosphatase (PTP) that regulates tyrosine phosphorylation levels and is involved in cell proliferation, differentiation and survival.
    SHP844
  • HY-171960
    SHP2-IN-40
    Inhibitor
    SHP2-IN-40 (Compound 25) is an inhibitor of SHP2 with an AC50 of 0.0107 μM. SHP2-IN-40 can be used in the research of cancer.
    SHP2-IN-40
  • HY-N10079
    Suchilactone
    Inhibitor
    Suchilactone (Jatrophan) is a lignan extracted from Monsonia angustifolia E.Mey. Suchilactone binds to SHP2 and inhibits SHP2 activation, thereby inhibiting ERK-mediated cell proliferation. Suchilactone can be ued in acute myeloid leukaemia (AML).
    Suchilactone
  • HY-155277
    SHP2-IN-21
    SHP2-IN-21 (compound 208) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-21 can be used for glioblastoma research.
    SHP2-IN-21
  • HY-155274
    SHP2-IN-18
    SHP2-IN-18 (compound 183) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-18 can be used for glioblastoma research.
    SHP2-IN-18
  • HY-162755
    SHP2-IN-30
    Inhibitor
    SHP2-IN-30 (compound 14i) is an allosteric SHP2 inhibitor with an IC50 of 104 nM. SHP2-IN-30 shows low inhibitory effect on SHP2-PTP. SHP2-IN-30 induces cell apoptosis and arrests the cell cycle at the G0/G1 phase.
    SHP2-IN-30
  • HY-158762
    TK-642
    Inhibitor
    TK-642 is a highly active, selective, orally activity SHP2 inhibitor based on pyrazole and pyrazine (IC50=2.7 nmol/L). TK-642 can effectively inhibit the proliferation of esophageal carcinoma cells and induce cell apoptosis. TK-642 can be used in the study of esophageal cancer.
    TK-642
  • HY-P3444A
    CD31 TFA
    CD31 (PECAM-1) TFA is platelet endothelial cell adhesion molecule-1, serves as the endothelial cell-specific receptor of clostridium perfringens b-Toxin (CPB). CD31 TFA is also an ER-MP12 antigen, acts as a linker between mechanical stress, metabolism and inflammation. CD31 TFA peptide is able to sustain phosphorylation of the CD31 ITIM686 and of SHP2 and to inhibit TCR-induced T-cell activation-.
    CD31 TFA
  • HY-159489
    SDUY038
    Inhibitor
    SDUY038 is a SHP2 allosteric inhibitor, with an IC50 of 1.2 μM and KD of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC50 = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t1/2 of 3.95 h by oral administration.
    SDUY038
Cat. No. Product Name / Synonyms Application Reactivity